Economics of the clinical management of lung cancer in France: an analysis using a Markov model-Reference-Cited by-同舟云学术

Economics of the clinical management of lung cancer in France: an analysis using a Markov model

Published:2004-01 Issue:2 Volume:90 Page:397-402
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Chouaïd C,Molinier L,Combescure C,Daurès J P,Housset B,Vergnenègre A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6601547.pdf

Reference25 articles.

1. Arikian SR, Suver J, Einarson T, Doyle J (1995) Economic and quality of life outcomes: the four-step pharmacoeconomic research model. Oncology (Huntington) 9: 33–36

2. Bahl A, Falk S (2001) Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br J Cancer 84: 1143–1145

3. Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O'Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS (2000) Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project. J Clin Oncol 18: 2805–2810

4. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L (2000) Decision framework for chemotherapic interventions for metastatic non small cell lung cancer. J Nat Cancer Inst 92: 1321–1329

5. Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B (1998) Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 16: 2700–2707

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States;Value in Health Regional Issues;2023-11

2. Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France;Journal of Medical Economics;2022-05-30

3. Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers;JCO Clinical Cancer Informatics;2021-02

4. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France;Lung Cancer;2019-01

5. Les coûts du cancer du poumon;Revue des Maladies Respiratoires Actualités;2018-10